Thursday, August 13, 2026 SourcesAbout🌓
🇨🇦 CA ▾
BREAKING
Luigi Mangione expected to plead guilty to federal stalking charges Trump slaps new tariffs on drones, including from some key U.S. allies ‘When the team doesn’t win, it’s hard to celebrate’: Scherzer on recording 3,000 innings Madison Pacific Properties Inc. announces the results for the six months ended June 30, 2026 and declares dividend Brookfield’s Bruce Flatt says wider industry’s private credit woes aren’t a systemic problem Osisko Gold Reports Second Quarter 2026 Results Blue Jays' bats cooled in matinee but take series from Red Sox, remain in playoff hunt MANDEL: Toronto widow killer free on parole – and he can now drink in bars Peter Maher was voice of Calgary, not just Flames 45th annual Carifest returns to downtown Calgary this weekend Luigi Mangione expected to plead guilty to federal stalking charges Trump slaps new tariffs on drones, including from some key U.S. allies ‘When the team doesn’t win, it’s hard to celebrate’: Scherzer on recording 3,000 innings Madison Pacific Properties Inc. announces the results for the six months ended June 30, 2026 and declares dividend Brookfield’s Bruce Flatt says wider industry’s private credit woes aren’t a systemic problem Osisko Gold Reports Second Quarter 2026 Results Blue Jays' bats cooled in matinee but take series from Red Sox, remain in playoff hunt MANDEL: Toronto widow killer free on parole – and he can now drink in bars Peter Maher was voice of Calgary, not just Flames 45th annual Carifest returns to downtown Calgary this weekend
Business

BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026

Financial Post ·

MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on Thursday, August 13, 2026 after market hours. A presentation on the Company’s second quarter and first half 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.

A welcome email is on its way. If you don't see it, please check your junk folder.

As of the date of this press release, the Company has 11,312,635 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com .

Mr. René C. Goehrum President and CEO BioSyent Inc. E-Mail: [email protected] Phone: 905-206-0013 Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

More from Financial Post

See all ›

More in Business

See all ›